AstraZeneca won't advertise its new indication

Share this article:
AstraZeneca will not run TV or print ads for its recently approved pediatric indication on Nexium. The firm told the Delaware News Journal it would instead partner with patient advocacy groups to inform doctors that the drug is now approved as an acid reflux treatment for children ages 12–17.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.